Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA v...

Full description

Bibliographic Details
Main Authors: George W. Carnell, Martina Billmeier, Sneha Vishwanath, Maria Suau Sans, Hannah Wein, Charlotte L. George, Patrick Neckermann, Joanne Marie M. Del Rosario, Alexander T. Sampson, Sebastian Einhauser, Ernest T. Aguinam, Matteo Ferrari, Paul Tonks, Angalee Nadesalingam, Anja Schütz, Chloe Qingzhou Huang, David A. Wells, Minna Paloniemi, Ingo Jordan, Diego Cantoni, David Peterhoff, Benedikt Asbach, Volker Sandig, Nigel Temperton, Rebecca Kinsley, Ralf Wagner, Jonathan L. Heeney
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Immunology
Subjects:
SARS-CoV-2 antibody
receptor binding domain (RBD)
glycan masking
neutralising antibodies
pseudotype neutralisation
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1118523/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1118523/full

Similar Items